ILIAD-7-BRA: InterLeukin-7 to Improve Clinical Outcomes in Lymphopenic pAtients With COVID-19 Infection (Brazil Cohort)

Sponsor
Revimmune (Industry)
Overall Status
Terminated
CT.gov ID
NCT04927169
Collaborator
ReSolution Latin America S.A. (Other)
4
6
2
12.9
0.7
0.1

Study Details

Study Description

Brief Summary

Comparison of the effects of CYT107 vs Placebo administered by intra-muscular route (IM) at 10μg/kg twice a week for three weeks on immune reconstitution of lymphopenic COVID-19 patients

Condition or Disease Intervention/Treatment Phase
Phase 2

Detailed Description

Approximately forty-eight (48) participants will be randomized 1:1 to receive

(a) Intramuscular (IM) administration of CYT107 at 10 μg/kg followed, after 72hrs of observation, by 10 μg/kg twice a week for 3 weeks (maximum 7administrations adjusted to patient's length of stay in the hospital) or (b)Intramuscular (IM) placebo (normal saline) at the same frequency. The aim of the study is to test the ability of CYT107 to produce an immune reconstitution of these patients and observe possible association with a clinical improvement.

This cohort excludes oncology patients on treatment

Study Design

Study Type:
Interventional
Actual Enrollment :
4 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
randomized controlled of treatment vs placeborandomized controlled of treatment vs placebo
Masking:
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Masking Description:
Unblinded Pharmacist will prepare blinded syringes of colorless drug or placebo
Primary Purpose:
Treatment
Official Title:
Recombinant Human InterLeukin-7 (CYT107) to Improve Clinical Outcomes in Lymphopenic PAtients With COVID-19 Infection - "ILIAD 7 Trial" Brazil Cohort
Actual Study Start Date :
Mar 1, 2021
Actual Primary Completion Date :
Dec 31, 2021
Actual Study Completion Date :
Mar 30, 2022

Arms and Interventions

Arm Intervention/Treatment
Experimental: CYT107

IM administration of CYT107 / Interleukin-7

Drug: Interleukin-7
IM administration at 10μg/kg twice a week for three weeks and up to 7 administrations according to Hospital length of stay
Other Names:
  • CYT107
  • Placebo Comparator: PLACEBO

    IM administration of Saline at the same volume

    Drug: PLACEBO
    IM administration of a volume of saline identical to 10μg/kg CYT107, twice a week for three weeks and up to 7 administrations according to Hospital length of stay
    Other Names:
  • SALINE
  • Outcome Measures

    Primary Outcome Measures

    1. Change of the absolute lymphocyte count (ALC) of lymphopenic (ALC≤1000/mm3) COVID-19 infected participants out to approximately 30 days following initial Study drug administration or Hospital discharge (HD), whichever occurs first [one month]

      A statistically significant increase of the absolute lymphocyte count (ALC) from randomization to day 30 or Hospital Discharge

    Secondary Outcome Measures

    1. To obtain "clinical improvement" as defined by an improvement in a 11-points WHO score for Clinical Assessment, through day 30 or HD. [one month]

      to determine if CYT107 will improve the clinical status of hospitalized COVID-19 patients as measured by the 11 points WHO clinical score

    2. a significant change of SARS-CoV-2 viral load through day 30 or HD [one month]

      The decrease of SARS-CoV-2 viral load from measurements at baseline and days of treatment dose 4 and dose 5, Day 21 and Day 30 or HD (whichever occurs first)

    3. frequency of secondary infections through day 45 compared to placebo arm [45 days]

      Incidence of secondary infections based on pre-specified criteria as adjudicated by the Secondary Infections Committee (SIC) through Day 45

    4. length of hospitalization compared to placebo arm [45 days]

      Number of days of hospitalization during index hospitalization (defined as time from initial Study drug treatment through HD)

    5. Length of stay in ICU compared to placebo arm [45 days]

      Number of days in ICU during index hospitalization

    6. number of readmissions to ICU compared to placebo arm [45 days]

      Readmissions to ICU through Day 45

    7. organ support free days compared to placebo arm [45 days]

      Organ support free days (OSFDs) during index hospitalization (This includes ventilator assistance free days)

    8. Frequency of re-hospitalization through day 45 compared to placebo arm [45 days]

      Number of readmissions to the hospital through Day 45

    9. All-cause mortality through day 45 compared to placebo arm [45 days]

      All-cause mortality through Day 45

    10. CD4+ and CD8+ T cell counts compared to placebo arm [30 days]

      Absolute numbers of CD4+ and CD8+ T-cell counts at time points indicated on the Schedule of Activities (SoA)through Day 30 or HD

    11. level of other known biomarkers of inflammation: Ferritin compared to placebo [30 days]

      Track and evaluate other known biomarkers of inflammation, Ferritin, from baseline to day 30

    12. Level of other known biomarkers of inflammation: C reactive protein level (CRP) compared to placebo arm [30 days]

      Level of other known biomarkers of inflammation: CRP compared to placebo arm

    13. Level of other known biomarkers of inflammation: D-dimer compared to placebo arm [30 days]

      Track and evaluate other known biomarkers of inflammation, D-dimer from baseline to day 30

    14. Physiological status through National Early Warning Score (NEWS2) evaluation compared to Placebo arm [30 days]

      Evaluate chnage of the NEWS2 score value. Score form 0 to 4: NO Risk Score of 7 or more: High risk

    Other Outcome Measures

    1. Safety assessment through incidence and scoring of grade 3-4 adverse events [45 days]

      Incidence and scoring of all grade 3-4 adverse events through Day 45 (using CTCAE Version 5.0) to assess safety

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    25 Years to 80 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    1. A written, signed informed consent, or emergency oral consent, by the patient or the patient's legally authorized representative, and the anticipated ability for participant to be re-consented in the future for ongoing Study participation

    2. Men and women aged ≥ 25 - 80 (included) years of age

    3. Hospitalized patients with two absolute lymphocyte count (ALC) ≤ 1000 cells/mm3, at two time points at least 24 hours apart, following HOSPITALIZATION:

    4. Hospitalized patients with moderate to severe hypoxemia requiring oxygen therapy at

    4L per minute nasal cannula or greater to keep saturations >90%, non-invasive positive pressure ventilation (e.g., BIPAP), or patients intubated / ventilated for respiratory failure

    1. Confirmed infection with COVID-19 by any acceptable test available / utilized at each site

    2. Willingness and ability to practice contraception regardless of the gender of the patient during 5 months after last drug exposure

    3. Private insurance or government / institution financial support (through CMS or other)

    Exclusion Criteria:
    1. Pregnancy or breast feeding

    2. ALT and/or AST > 5 x ULN

    3. Known, active auto-immune disease;

    4. Ongoing cancer treatment with chemotherapy / immunotherapy or any cancer therapy within last 3 months and/or ongoing

    5. Patients with past history of Solid Organ transplant

    6. Active tuberculosis, uncontrolled active HBV or HCV infection, HIV with positive viral load

    7. Hospitalized patients with refractory hypoxia, defined as inability to maintain saturation >85% with maximal available therapy for >6 hours

    8. Patients receiving any agent with immune suppressive effects, other than steroids at dosages less than 300 mg/day equivalent hydrocortisone and/or anti-IL-6R treatments like Tocilizumab or Sarilumab or anti-IL-1 treatment like Anakinra which should preferably be minimized

    9. Patients with baseline Rockwood Clinical Frailty Scale ≥ 6 at Hospital admission

    10. Patients showing an increase of the NEWS2 score by more than 6 points during the screening/ baseline period (48 to 72 hrs prior to first administration)

    11. Patients under guardianship

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Hospital de Clinicas de Porto Alegre Porto Alegre RIO Grande DO SUL Brazil 90035
    2 Hospital Sao Jose São José Santa Catarina Brazil 88103
    3 Upeclin-Unesp Botucatu SAO Paolo Brazil 18618
    4 Hospital Das Clinicas de Ribeirao Preto Monte Alegre SAO Paolo Brazil 14051
    5 Universidade Federal de Sao Paolo São Paulo SAO Paolo Brazil 04021
    6 Hospital Edmundo Vasconcelos Vila Clementino SAO Paolo Brazil 04038

    Sponsors and Collaborators

    • Revimmune
    • ReSolution Latin America S.A.

    Investigators

    • Principal Investigator: Reinaldo SALOMAO, MD, Escola Paulista de Medicina Universidade Federal de São Paulo

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Revimmune
    ClinicalTrials.gov Identifier:
    NCT04927169
    Other Study ID Numbers:
    • ILIAD-7 BRAZIL
    First Posted:
    Jun 15, 2021
    Last Update Posted:
    Apr 8, 2022
    Last Verified:
    Mar 1, 2022
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    Yes
    Studies a U.S. FDA-regulated Device Product:
    No
    Product Manufactured in and Exported from the U.S.:
    Yes
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Apr 8, 2022